JP2021522264A - 抗微生物有効性の増強及び毒性の減少を有する亜塩素酸ナトリウム組成物 - Google Patents
抗微生物有効性の増強及び毒性の減少を有する亜塩素酸ナトリウム組成物 Download PDFInfo
- Publication number
- JP2021522264A JP2021522264A JP2020560205A JP2020560205A JP2021522264A JP 2021522264 A JP2021522264 A JP 2021522264A JP 2020560205 A JP2020560205 A JP 2020560205A JP 2020560205 A JP2020560205 A JP 2020560205A JP 2021522264 A JP2021522264 A JP 2021522264A
- Authority
- JP
- Japan
- Prior art keywords
- sodium chlorite
- eye
- composition
- composition according
- disinfectant composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 191
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 title claims abstract description 131
- 229960002218 sodium chlorite Drugs 0.000 title claims abstract description 129
- 230000000845 anti-microbial effect Effects 0.000 title claims description 23
- 230000002829 reductive effect Effects 0.000 title description 3
- 231100000419 toxicity Toxicity 0.000 title description 2
- 230000001988 toxicity Effects 0.000 title description 2
- 239000000645 desinfectant Substances 0.000 claims abstract description 58
- 239000004094 surface-active agent Substances 0.000 claims abstract description 46
- 230000001954 sterilising effect Effects 0.000 claims abstract description 12
- 239000000872 buffer Substances 0.000 claims description 75
- -1 tinctures Substances 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000002736 nonionic surfactant Substances 0.000 claims description 23
- 239000002674 ointment Substances 0.000 claims description 16
- 210000004087 cornea Anatomy 0.000 claims description 11
- 238000001356 surgical procedure Methods 0.000 claims description 11
- 230000000699 topical effect Effects 0.000 claims description 11
- 239000006196 drop Substances 0.000 claims description 10
- 210000000744 eyelid Anatomy 0.000 claims description 10
- 239000000499 gel Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 8
- 239000003889 eye drop Substances 0.000 claims description 8
- 239000006260 foam Substances 0.000 claims description 8
- 239000006210 lotion Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 206010010741 Conjunctivitis Diseases 0.000 claims description 6
- 210000003467 cheek Anatomy 0.000 claims description 6
- 210000004709 eyebrow Anatomy 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 206010072170 Skin wound Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 25
- 210000001508 eye Anatomy 0.000 description 73
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 43
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 41
- 229920000053 polysorbate 80 Polymers 0.000 description 41
- 210000001519 tissue Anatomy 0.000 description 36
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 35
- 229920000153 Povidone-iodine Polymers 0.000 description 30
- 229960001621 povidone-iodine Drugs 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 229940068968 polysorbate 80 Drugs 0.000 description 27
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 26
- 230000002147 killing effect Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- 239000004155 Chlorine dioxide Substances 0.000 description 13
- 235000019398 chlorine dioxide Nutrition 0.000 description 13
- 235000014113 dietary fatty acids Nutrition 0.000 description 13
- 239000000194 fatty acid Substances 0.000 description 13
- 229930195729 fatty acid Natural products 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000004913 activation Effects 0.000 description 12
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 10
- 229920001992 poloxamer 407 Polymers 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 210000000795 conjunctiva Anatomy 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 239000002357 osmotic agent Substances 0.000 description 7
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 239000004599 antimicrobial Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002997 ophthalmic solution Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000004382 visual function Effects 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 229940064804 betadine Drugs 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 229940054534 ophthalmic solution Drugs 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000004304 visual acuity Effects 0.000 description 5
- 206010015946 Eye irritation Diseases 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 239000007979 citrate buffer Substances 0.000 description 4
- 231100000013 eye irritation Toxicity 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 229940090942 povidone-iodine ophthalmic solution Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960002303 citric acid monohydrate Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000002690 local anesthesia Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 239000006150 trypticase soy agar Substances 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- HDTIFOGXOGLRCB-VVGYGEMISA-N 2-[2-[(2r,3r)-3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOCC(OCCO)[C@H]1OCC(OCCO)[C@H]1OCCO HDTIFOGXOGLRCB-VVGYGEMISA-N 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229910001919 chlorite Inorganic materials 0.000 description 2
- 229910052619 chlorite group Inorganic materials 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003560 epithelium corneal Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229920005610 lignin Chemical class 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 201000005111 ocular hyperemia Diseases 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 229960004418 trolamine Drugs 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010061137 Ocular toxicity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920001304 Solutol HS 15 Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- 206010044245 Toxic optic neuropathy Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 150000001253 acrylic acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940077239 chlorous acid Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- CDMADVZSLOHIFP-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;decahydrate Chemical group O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 CDMADVZSLOHIFP-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 210000000826 nictitating membrane Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000036439 ocular surface hyperemia Effects 0.000 description 1
- 231100000327 ocular toxicity Toxicity 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical class [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical class C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012619 stoichiometric conversion Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
Abstract
Description
5%ポビドン−ヨードと比較した亜塩素酸ナトリウム組成物の抗微生物死滅有効性
Staphylococcus aureus ATCC29213(S.aureus)に対して時間死滅有効性実験を行った。Tryptic Soy寒天(TSA)を有するプレートに、S.aureusの培養物を接種し、30〜35℃で24時間インキュベートした。細菌培養物を回収し、試料懸濁液を、1ミリリットル当たり約105〜106コロニー形成単位(CFU)を含有するように調節した。各試験について、界面活性剤の有又は無の被験試料(Betadine(登録商標)5%Sterile Ophthalmic Prep Solution(ポビドン−ヨード眼科用溶液;Alcon,FortWorth,TX)又は亜塩素酸ナトリウム)の10mLを、滅菌ガラス試験管に分配し、100μLのS.aureus懸濁液を接種し、よく混合した。亜塩素酸ナトリウムを、それらのpHが異なる(pH5、pH4、pH3、又はpH2)4つの緩衝液のうちの1つで30秒間〜最大5分間活性化し、次いで分配した。30秒の曝露後、1mLの試験懸濁液を除去し、Dey−Engley中和剤の9.0mLに添加した。この中和懸濁液の100μLを、自動スパイラルプレーティング装置(Edddyjet2,Neutec group Inc,New York,USA)を使用して、7対数連続希釈モードでTSAプレート上に3反復でプレーティングした。全ての細菌プレートを、30〜35℃で2日間インキュベートした。対数液滴値を、被験試料の有又は無のプレートの対数化されたCFUの差として決定する。
5%ポビドン−ヨードと比較した亜塩素酸ナトリウム組成物の眼における安全性及び耐容性
非鎮静ウサギにおいて眼の安全性及び耐容性実験を実施し、1)上皮細胞の完全性の指標である、局所用フルオレセインナトリウムによる角膜染色の評価、2)刺激の指標である、眼の表面充血の評価、並びに、3)角膜の損傷によって視機能が影響を受ける程度の指標である、視力の評価が得られた。
実施形態P1.組織を殺菌するための消毒組成物であって、組成物が、亜塩素酸ナトリウムを含む、消毒組成物。
実施形態P2.亜塩素酸ナトリウムが、約800ppm〜約8000ppmの量である、条項1に記載の消毒組成物。
実施形態P3.亜塩素酸ナトリウムが、5以下であるpHを有する緩衝液中で活性化される、条項1又は2に記載の消毒組成物。
実施形態P4.亜塩素酸ナトリウムが、最大約7.6であるpHを有する緩衝液中で活性化される、条項1又は2に記載の消毒組成物。
実施形態P5.界面活性剤をさらに含む、条項1〜4のいずれか一つに記載の消毒組成物。
実施形態P7.非イオン性界面活性剤が、ポリオキシエチレンソルビタンモノオレエート、ポリオキシエチレンラウリルエーテル、及びポリ(エチレングリコール)−ブロック−ポリ(プロピレングリコール)−ブロック−ポリ(エチレングリコール)からなる群から選択される、条項6に記載の消毒組成物。
実施形態P8.組成物が、抗微生物活性を有する、条項1〜7のいずれか一つに記載の消毒組成物。
実施形態P9.組成物が、水溶液、エマルジョン(水中油又は油中水)、ローション、クリーム、軟膏、膏薬(salves)、ゲル、滴下、フォーム、粉末、チンキ、及び固形剤からなる群から選択される形態である、条項1〜8のいずれか一つに記載の消毒組成物。
実施形態P10.組成物が、点眼剤、洗眼剤、洗眼剤(swab)、又は眼浴剤の形態である、条項1〜9のいずれか一つに記載の消毒組成物。
実施形態P12.殺菌される組織が、眼瞼、眉間、頬、角膜、結膜炎、又は眼瞼円蓋(palpebral fornix)を含む、条項1〜10のいずれか一つに記載の消毒組成物。
実施形態P13.組織の殺菌のための医薬品の調製のための組成物の使用であって、組成物が、緩衝液中で活性化された亜塩素酸ナトリウムを含む、組成物の使用。
実施形態P14.組成物が、約800ppm〜約8000ppmの量の亜塩素酸ナトリウムを含む、条項13に記載の組成物。
実施形態P15.緩衝液が、5以下であるpHを有する、条項13又は14に記載の組成物。
実施形態P17.組成物が、界面活性剤を含む、条項13〜16のいずれか一つに記載の組成物。
実施形態P18.界面活性剤が、0.015w/v%〜約0.5w/v%の量の非イオン性界面活性剤である、条項17に記載の組成物。
実施形態P19.非イオン性界面活性剤が、ポリオキシエチレンソルビタンモノオレエート、ポリオキシエチレンラウリルエーテル、及びポリ(エチレングリコール)−ブロック−ポリ(プロピレングリコール)−ブロック−ポリ(エチレングリコール)からなる群から選択される、条項18に記載の組成物。
実施形態P20.組成物が、抗微生物活性を有する、条項13〜19のいずれか一つに記載の組成物。
実施形態P22.組成物が、点眼剤、洗眼剤、洗眼剤(swab)、又は眼浴剤の形態である、条項13〜21のいずれか一つに記載の組成物。
実施形態P23.殺菌される組織が、皮膚、皮膚創傷、又は皮膚切開を含む、条項13〜22のいずれか一つに記載の組成物。
実施形態P24.殺菌される組織が、眼瞼、眉、頬、角膜、結膜炎、又は眼瞼円蓋(palpebral fornix)を含む、条項13〜22のいずれか一つに記載の組成物。
実施形態P26.消毒組成物が、約800ppm〜約8000ppmの量で亜塩素酸ナトリウムを含む、条項25に記載の方法。
実施形態P27.亜塩素酸ナトリウムが、5以下であるpHを有する緩衝液中で活性化される、条項25又は26に記載の方法。
実施形態P28.亜塩素酸ナトリウムが、最大約7.6であるpHを有する緩衝液中で活性化される、条項25又は26に記載の方法。
実施形態P29.消毒組成物が、界面活性剤をさらに含む、条項25〜28のいずれか一つに記載の方法。
実施形態P30.界面活性剤が、0.015w/v%〜約0.5w/v%の量の非イオン性界面活性剤である、条項29に記載の方法。
実施形態P32.消毒組成物が、抗微生物活性を有する、条項25〜31のいずれか一つに記載の方法。
実施形態P33.消毒組成物が、水溶液、エマルジョン(水中油又は油中水)、ローション、クリーム、軟膏、膏薬(salve)、ゲル、滴下、フォーム、粉末、チンキ、及び固形剤からなる群から選択される形態である、条項25〜32のいずれか一つに記載の方法。
実施形態P34.消毒組成物が、点眼剤、洗眼剤、洗眼剤(swab)、又は眼浴剤の形態である、条項25〜33のいずれか一つに記載の方法。
実施形態P35.組織が、皮膚、皮膚創傷、又は皮膚切開を含む、条項25〜34のいずれか一つに記載の方法。
実施形態P36.殺菌される組織が、眼瞼、眉間、頬、角膜、結膜炎、又は眼瞼円蓋(palpebral fornix)を含む、条項25〜34のいずれか一つに記載の方法。
実施形態P38.条項25〜36のいずれか一つに記載の処置方法のための条項1〜12のいずれか一つに記載の消毒組成物の使用。
実施形態P40.界面活性剤が、ポリオキシエチレンソルビタンモノオレエートである、条項39に記載の組成物。
実施形態P41.組成物が、約8000ppmの亜塩素酸ナトリウム、約0.5w/v%のポリオキシエチレンソルビタンモノオレエート、約0.83w/v%のリン酸ナトリウム一塩基性一水和物、約0.17w/v%のクエン酸一水和物、塩酸及び/又は水酸化ナトリウム、並びに水を含み、組成物が、約5のpHを有する、条項39に記載の組成物。
実施形態P42.組成物が、約8000ppmの亜塩素酸ナトリウム、約0.5w/v%のポリオキシエチレンソルビタンモノオレエート、約0.25w/v%のリン酸ナトリウム一塩基性一水和物、約0.35w/v%のクエン酸一水和物、及び水を含み、組成物が、約4のpHを有する、条項39に記載の組成物。
実施形態P43.組成物が、約8000ppmの亜塩素酸ナトリウム、約0.5w/v%のポリオキシエチレンラウリルエーテル、約0.83w/v%のリン酸ナトリウム一塩基性一水和物、約0.17w/v%のクエン酸一水和物、塩酸及び/又は水酸化ナトリウム、並びに水を含み、組成物が、約5のpHを有する、条項39に記載の組成物。
実施形態P45.少なくとも1つの緩衝液が、リン酸緩衝液、クエン酸緩衝液、又はホウ酸緩衝液である、条項39に記載の組成物。
実施形態P46.組成物が、5以下のpHを有する、条項39に記載の組成物。
実施形態P48.処置が、消毒組成物を、患者の眼に局所的に適用することを含む、条項47に記載の方法。
実施形態P49.消毒組成物を眼に局所的に適用することが、消毒組成物を外科的手技前、外科手技中、及び/又は外科手技後に局所的に適用することを含む、条項48に記載の方法。
実施形態P51.亜塩素酸ナトリウムが、約800ppm〜約8000ppmの量である、条項50に記載の組成物の眼における使用。
実施形態P52.界面活性剤が、約0.015w/v%〜約0.5w/v%の量である、条項50又は51に記載の組成物の眼における使用。
実施形態P53.組成物が、5以下のpHを有する少なくとも1つの緩衝液をさらに含む、条項50〜52のいずれか1つの組成物の眼における使用。
実施形態P54.組成物が、眼組織に局所的に適用される、条項50〜53のいずれか1つの組成物の眼における使用。
実施形態P55.組成物が、眼の外科的手技前、外科手技中、及び/又は外科手技後に眼組織に局所的に適用される、条項54に記載の組成物の眼における使用。
本出願は、2018年4月27日に出願された同時係属中の米国仮特許出願第62/663,886号の米国特許法第119条(e)に基づく優先権の利益を主張する。本仮特許出願の開示は、参照によりその全体が本明細書に組み込まれる。
Claims (15)
- 組織を殺菌するための消毒組成物であって、
亜塩素酸ナトリウムを含む、消毒組成物。 - 前記亜塩素酸ナトリウムが、約800ppm〜約8000ppmの量である、請求項1に記載の消毒組成物。
- 前記亜塩素酸ナトリウムが、5以下であるpHを有する緩衝液中で活性化される、請求項1又は2に記載の消毒組成物。
- 前記亜塩素酸ナトリウムが、最大約7.6であるpHを有する緩衝液中で活性化される、請求項1又は2に記載の消毒組成物。
- 界面活性剤をさらに含む、請求項1〜4のいずれか一項に記載の消毒組成物。
- 前記界面活性剤が、0.015w/v%〜約0.5w/v%の量の非イオン性界面活性剤である、請求項5に記載の消毒組成物。
- 抗微生物活性を有する、請求項1〜6のいずれか一項に記載の消毒組成物。
- 水溶液、乳剤(水中油又は油中水)、化粧水、クリーム、軟膏、膏薬(salve)、ゲル、滴下、フォーム、粉末、チンキ、及び固形剤からなる群から選択される形態である、請求項1〜7のいずれか一項に記載の消毒組成物。
- 点眼剤、洗眼剤、洗眼剤(swab)、又は眼浴剤の形態である、請求項1〜7のいずれか一項に記載の消毒組成物。
- 組織の殺菌のための医薬品の調製のための、請求項1〜9のいずれか一項に記載の消毒組成物の使用。
- 殺菌される組織が、皮膚、皮膚創傷、又は皮膚切開部を含む、請求項10に記載の組成物。
- 殺菌される組織が、眼瞼、眉、頬、角膜、結膜炎、又は眼瞼円蓋(palpebral fornix)を含む、請求項11に記載の組成物。
- 前記組織が、眼組織である、請求項10に記載の組成物。
- 前記使用が、前記消毒組成物を、患者の眼に局所的に適用することを含む、請求項13に記載の組成物。
- 前記消毒組成物を、前記眼に局所的に適用することが、前記消毒組成物を、外科的手技前、外科手技中、及び/又は外科手技後に局所的に適用することを含む、請求項14に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862663886P | 2018-04-27 | 2018-04-27 | |
US62/663,886 | 2018-04-27 | ||
PCT/US2019/029078 WO2019210041A1 (en) | 2018-04-27 | 2019-04-25 | Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021522264A true JP2021522264A (ja) | 2021-08-30 |
Family
ID=66821345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020560205A Pending JP2021522264A (ja) | 2018-04-27 | 2019-04-25 | 抗微生物有効性の増強及び毒性の減少を有する亜塩素酸ナトリウム組成物 |
Country Status (8)
Country | Link |
---|---|
US (3) | US11096958B2 (ja) |
EP (1) | EP3784354A1 (ja) |
JP (1) | JP2021522264A (ja) |
CN (1) | CN112272578A (ja) |
AU (1) | AU2019261437A1 (ja) |
CA (1) | CA3097998A1 (ja) |
TW (1) | TW202014194A (ja) |
WO (1) | WO2019210041A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220117869A1 (en) * | 2019-02-11 | 2022-04-21 | Reckitt Benckiser Health Limited | Topical sanitizing compositions |
JP2023523840A (ja) * | 2020-04-30 | 2023-06-07 | アイレニックス メディカル,インコーポレイテッド. | 増強された抗ウイルス及び抗微生物効果、並びに低減された毒性を有する、亜塩素酸ナトリウム組成物 |
WO2022031416A1 (en) * | 2020-08-04 | 2022-02-10 | Micropure, Inc. | Compositions and methods for prevention of viral infections and associated diseases |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03505203A (ja) * | 1988-05-06 | 1991-11-14 | アルサイド コーポレーション | 皮膚病および炎症性の病気のための抗炎症性および抗菌性製剤 |
JP2007527390A (ja) * | 2003-07-07 | 2007-09-27 | エル. カラジョージアン、ハンパー | 亜塩素酸塩及び過酸化水素を含有する相乗効果を備えた抗菌性の眼科用及び皮膚科用調製物 |
JP2008537954A (ja) * | 2005-04-15 | 2008-10-02 | イーコラブ インコーポレイティド | オレフィン安定剤を有する酸性化クロライト殺菌組成物 |
JP2014028857A (ja) * | 2008-02-07 | 2014-02-13 | Rohto Pharmaceut Co Ltd | メントール類を含有する亜塩素酸類化合物含有水性組成物 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE789533A (fr) | 1971-09-29 | 1973-03-29 | Hoechst Ag | Blanchiment au moyen de chlorites |
US4330531A (en) | 1976-03-26 | 1982-05-18 | Howard Alliger | Germ-killing materials |
US4084747A (en) * | 1976-03-26 | 1978-04-18 | Howard Alliger | Germ killing composition and method |
US4499077A (en) | 1981-02-03 | 1985-02-12 | Stockel Richard F | Anti-microbial compositions and associated methods for preparing the same and for the disinfecting of various objects |
US4689215A (en) | 1984-07-30 | 1987-08-25 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US4902498A (en) | 1988-06-01 | 1990-02-20 | The Procter & Gamble Company | Oral compositions |
IL92351A (en) | 1988-11-29 | 1994-02-27 | Allergan Inc Irvine | Optimal aqueous solutions containing stabilized chlorine acid and inorganic salt |
TW200402B (ja) * | 1990-08-13 | 1993-02-21 | Senju Pharma Co | |
US5667817A (en) | 1992-03-20 | 1997-09-16 | Alcide Corporation | Method and composition for prevention and treatment of female lower genital tract microbial infections |
AU676528B2 (en) * | 1992-12-17 | 1997-03-13 | Advanced Medical Optics, Inc. | Contact lens disinfecting solution containing sodium chlorite and polyvinyl pyrrolidone |
US6200557B1 (en) | 1993-07-06 | 2001-03-13 | Perry A. Ratcliff | Method of treating HIV by a topical composition |
US5489435A (en) | 1993-07-06 | 1996-02-06 | Ratcliff; Perry A. | Composition for treatment of abnormal conditions of the epithelium of bodily orifices |
NZ335780A (en) * | 1996-10-23 | 2001-01-26 | Univ New York State Res Found | Compositions to control oral microbial oxidation-reduction (Eh) levels and treat gingivitis-periodontitis |
US6277363B1 (en) | 1998-09-21 | 2001-08-21 | Vortech, Inc. | Method and composition for treating chlamydia infection |
WO2000019981A1 (en) | 1998-10-08 | 2000-04-13 | Karagoezian Hampar L | Synergistic antimicrobial, dermatological and ophthalmic preparations containing chlorite and hydrogen peroxide |
US7923469B2 (en) * | 2001-04-30 | 2011-04-12 | Allergen, Inc. | Compositions including vitamin-based surfactants and methods for using same |
WO2003082304A1 (en) | 2002-03-27 | 2003-10-09 | Kling William O | Antimicrobial compositions and methods of use |
US20040137079A1 (en) | 2003-01-08 | 2004-07-15 | Cook James N. | Contact lens and eye drop rewetter compositions and methods |
US20040185068A1 (en) | 2003-03-18 | 2004-09-23 | Zhi-Jian Yu | Self-emulsifying compositions, methods of use and preparation |
US7578996B2 (en) * | 2004-04-07 | 2009-08-25 | Advanced Medical Optics, Inc. | Cetylpyridinium chloride as an antimicrobial agent in ophthalmic compositions |
US20050276867A1 (en) * | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative |
GB0414244D0 (en) | 2004-06-25 | 2004-07-28 | Ebiox Ltd | Composition |
DE102005006462A1 (de) | 2005-02-12 | 2006-09-07 | Templa Tech Gmbh | Mittel zur Behandlung von Infektionen |
WO2007007832A1 (ja) | 2005-07-13 | 2007-01-18 | Santen Pharmaceutical Co., Ltd. | 眼科用防腐組成物 |
MX2008006297A (es) | 2005-11-14 | 2008-09-19 | Cdg Technology Inc | Soluciones acuosas estables al almacenamiento de dioxido de cloruro y metodos para prepararlas y usarlas. |
US20070264226A1 (en) * | 2006-05-10 | 2007-11-15 | Karagoezian Hampar L | Synergistically enhanced disinfecting solutions |
US20080020064A1 (en) | 2006-07-21 | 2008-01-24 | Advanced Vision Research | Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear |
JP4598130B2 (ja) | 2007-02-16 | 2010-12-15 | 大幸薬品株式会社 | 保存安定性に優れた広域抗ウイルス薬剤組成物 |
EP2130795A4 (en) | 2007-03-15 | 2012-12-19 | Taiko Pharmaceutical Co Ltd | COMPOSITION FOR STABILIZING CHLORIDE DIOXIDE |
JP4670107B2 (ja) | 2007-03-27 | 2011-04-13 | 大幸薬品株式会社 | 感染性皮膚および粘膜疾患治療薬 |
US20090239775A1 (en) | 2008-03-19 | 2009-09-24 | Collins Gary L | Ophthalmic solutions displaying improved efficacy |
US20110212035A1 (en) | 2010-02-26 | 2011-09-01 | Collegium Pharmaceutical, Inc. | Emollient foams for treatment of dermatoses |
JP5865360B2 (ja) | 2010-06-11 | 2016-02-17 | プレシジョン ダーマトロジー インコーポレイテッドPrecision Dermatology, Inc. | 油分高濃度配合軟化性エアロゾル発泡組成物 |
CN103189049A (zh) | 2010-08-13 | 2013-07-03 | 努沃研究公司 | 稳定的亚氯酸盐的可发泡组合物 |
US9095134B2 (en) * | 2010-09-22 | 2015-08-04 | Ecolab Usa Inc. | Antimicrobial compositions containing cationic active ingredients and quaternary sugar derived surfactants |
US9314528B2 (en) | 2011-12-07 | 2016-04-19 | Allergan, Inc. | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system |
RU2014129268A (ru) | 2011-12-16 | 2016-02-10 | Аллерган, Инк. | Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля |
WO2013102048A2 (en) | 2011-12-30 | 2013-07-04 | University Of Miami | Regenerative tissue matrix |
CN106074692A (zh) | 2016-07-06 | 2016-11-09 | 李光新 | 一种复方稳定性二氧化氯溶液及其制备方法和应用 |
-
2019
- 2019-04-25 TW TW108114604A patent/TW202014194A/zh unknown
- 2019-04-25 EP EP19729916.7A patent/EP3784354A1/en active Pending
- 2019-04-25 CN CN201980028717.8A patent/CN112272578A/zh active Pending
- 2019-04-25 CA CA3097998A patent/CA3097998A1/en active Pending
- 2019-04-25 WO PCT/US2019/029078 patent/WO2019210041A1/en active Application Filing
- 2019-04-25 US US16/394,981 patent/US11096958B2/en active Active
- 2019-04-25 JP JP2020560205A patent/JP2021522264A/ja active Pending
- 2019-04-25 AU AU2019261437A patent/AU2019261437A1/en active Pending
-
2021
- 2021-07-15 US US17/376,757 patent/US11738043B2/en active Active
-
2023
- 2023-07-07 US US18/219,444 patent/US20240115599A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03505203A (ja) * | 1988-05-06 | 1991-11-14 | アルサイド コーポレーション | 皮膚病および炎症性の病気のための抗炎症性および抗菌性製剤 |
JP2007527390A (ja) * | 2003-07-07 | 2007-09-27 | エル. カラジョージアン、ハンパー | 亜塩素酸塩及び過酸化水素を含有する相乗効果を備えた抗菌性の眼科用及び皮膚科用調製物 |
JP2008537954A (ja) * | 2005-04-15 | 2008-10-02 | イーコラブ インコーポレイティド | オレフィン安定剤を有する酸性化クロライト殺菌組成物 |
JP2014028857A (ja) * | 2008-02-07 | 2014-02-13 | Rohto Pharmaceut Co Ltd | メントール類を含有する亜塩素酸類化合物含有水性組成物 |
Also Published As
Publication number | Publication date |
---|---|
US20190328773A1 (en) | 2019-10-31 |
US11738043B2 (en) | 2023-08-29 |
AU2019261437A1 (en) | 2020-12-17 |
WO2019210041A1 (en) | 2019-10-31 |
EP3784354A1 (en) | 2021-03-03 |
US20210338714A1 (en) | 2021-11-04 |
US11096958B2 (en) | 2021-08-24 |
US20240115599A1 (en) | 2024-04-11 |
CN112272578A (zh) | 2021-01-26 |
TW202014194A (zh) | 2020-04-16 |
CA3097998A1 (en) | 2019-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2010262898B2 (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes | |
US11738043B2 (en) | Sodium chlorite compositions with enhanced antimicrobial efficacy and reduced toxicity | |
JP5620264B2 (ja) | コンタクトレンズケアおよび薬剤組成物の防腐のためのリン脂質組成物 | |
TWI498122B (zh) | 含有硼酸鹽-多元醇複合物之水性藥學組成物 | |
JP6359217B2 (ja) | 新規ヨードフォア組成物および使用方法 | |
JP2010511707A (ja) | 亜塩素酸塩および過酸化水素を含む相乗的抗菌製剤 | |
MXPA04000764A (es) | Preparaciones sinergistas antimicrobianas oftalmicas y dermatologicas que contienen clorito y peroxido de hidrogeno. | |
TW201630614A (zh) | 無刺激性眼用聚乙烯吡咯啶酮-碘組成物 | |
JP2010527933A5 (ja) | ||
JPH08310959A (ja) | 非水性皮膚軟化剤入りヨードフォア製剤 | |
MXPA06000257A (es) | Preparaciones oftalmicas y dermatologicas antimicrobianas, sinergicas, que contienen clorito y peroxido de hidrogeno. | |
JPH1160505A (ja) | 防腐組成物 | |
KR101934767B1 (ko) | 신규한 안과용 조성물 및 사용 방법 | |
JP4801300B2 (ja) | 外用液状組成物 | |
CA3169401A1 (en) | Xanthan-based ophthalmic topical formulations with a reduced dosage regimen | |
JP2003300871A (ja) | 眼科用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220330 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230131 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230428 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230801 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231020 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240328 |